Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
Executive Summary
FDA’s approval of Bristol-Myers Squibb’s metastatic melanoma immunotherapy was granted only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.
You may also be interested in...
Phase III Survival Benefit Boosts Imbruvica’s Profile Ahead Of FDA’s CLL Decision
RESONATE study is halted after Pharmacyclics/Janssen’s Imbruvica shows a survival benefit as a monotherapy compared to GlaxoSmithKline’s Arzerra. Analysts expect results will pave way for off-label use ahead of FDA’s approval in CLL, though a delay for official clearance is possible.
Phase III Survival Benefit Boosts Imbruvica’s Profile Ahead Of FDA’s CLL Decision
RESONATE study is halted after Pharmacyclics/Janssen’s Imbruvica shows a survival benefit as a monotherapy compared to GlaxoSmithKline’s Arzerra. Analysts expect results will pave way for off-label use ahead of FDA’s approval in CLL, though a delay for official clearance is possible.
Immune Checkpoint Blockade: The New Big Idea In Cancer
Biologics that target immune checkpoints co-opted by cancer resistance have been significantly de-risked by the success of Bristol’s immunotherapy Yervoy and the progress of its Phase III candidate nivolumab. With six companies now testing candidates in the clinic, the class promises to have a big impact on oncology over the next several years, with the possibility of a next-generation approval by 2015.